Hyperlipidemia, Hypertension
Conditions
Keywords
Cardiometabolic abnormalities, Digital Interventions
Brief summary
The aim of this study is to construct a digital precision intervention system for cardiometabolism disorders based on the characteristics of the Chinese population, focusing on the core components of metabolic syndrome such as hypertension, hyperglycemia, and obesity. Through dynamic monitoring of wearable devices, the individualized risk factors (including genetic predisposition, lifestyle, and psychological factors) of metabolic disorders were systematically analyzed, and dynamic intervention strategies were formulated accordingly. The closed-loop management of monitor-feedback-optimization based on the digital platform will provide patients with one-stop metabolic risk assessment and panoramic health management plan, realizing a paradigm shift from generalized intervention to precise regulation. By reducing the abnormal fluctuations of key metabolic indicators such as blood pressure, blood glucose, and blood lipids, the risk of cardiovascular events will eventually be reduced, the long-term quality of life of patients will be improved, and a practical path of digital therapy can be promoted for the prevention and control of chronic diseases in China
Interventions
OTHERBracelet, assistant, APP: the golden triangle of smart life
The lifestyle intervention was carried out through the bracelet, Little Assistant and Keyhealth APP for 24 weeks, and the daily data synchronization of the APP and weekly AI feedback were performed. After 24 weeks, blood glucose, blood lipid, blood pressure, CAI and other indicators were monitored.
Sponsors
Shanghai 10th People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-65 years old; 2. Meet one of the following three conditions: 1. Diastolic hypertension (systolic blood pressure \< 140 MMHG and diastolic blood pressure ≥90mmHg) 2. Glycosylated hemoglobin (6.0-6.5) 3. Obesity (BMI≥28kg/m²) 4. Mild hyperlipemia: total cholesterol (TC) ≥5.2 mmol/L and \< 6.2 mmol/L, or low-density lipoprotein cholesterol (LDL-C) ≥3.4 mmol/L and \< 4.1 mmol/L 3. Antihypertensive or lipid-lowering medications have not been started 4. Use a smartphone and volunteer
Exclusion criteria
1. Complicated with chronic liver and kidney disease, coronary heart disease, heart failure and severe valvular disease 2. Previous cardiovascular and cerebrovascular events 3. Diastolic blood pressure ≥99mmHg 4. Glycated hemoglobin ≥6.5 5. Other life expectancy such as cancer is less than 5 years 6. Participate in other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in diastolic blood pressure after 24 weeks | 24 weeks following intervention |
Secondary
| Measure | Time frame |
|---|---|
| Values for changes in Hba1c or BMI or CAI after 24 weeks | 24 weeks following intervention |
Countries
China
Contacts
Primary ContactYi Zhang
Outcome results
None listed